Cargando…

Cardiovascular Toxicities Associated With Hydroxychloroquine and Azithromycin: An Analysis of the World Health Organization Pharmacovigilance Database

Detalles Bibliográficos
Autores principales:	Nguyen, Lee S., Dolladille, Charles, Drici, Milou-Daniel, Fenioux, Charlotte, Alexandre, Joachim, Mira, Jean-Paul, Moslehi, Javid J., Roden, Dan M., Funck-Brentano, Christian, Salem, Joe-Elie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2020
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7365677/ https://www.ncbi.nlm.nih.gov/pubmed/32442023 http://dx.doi.org/10.1161/CIRCULATIONAHA.120.048238

Ejemplares similares

Response to the editorial “COVID-19 in patients with cardiovascular diseases”: Covid-19 treatment with hydroxychloroquine or chloroquine and azithromycin: A potential risk of Torsades de Pointes
por: Funck-Brentano, Christian, et al.
Publicado: (2020)

Retraction and republication: cardiac toxicity of hydroxychloroquine in COVID-19
por: Funck-Brentano, Christian, et al.
Publicado: (2020)

Systematic analysis of drug-associated myocarditis reported in the World Health Organization pharmacovigilance database
por: Nguyen, Lee S., et al.
Publicado: (2022)

Cardiotoxicity Associated with Gemcitabine: Literature Review and a Pharmacovigilance Study
por: Hilmi, Marc, et al.
Publicado: (2020)

RETRACTED: Chloroquine or hydroxychloroquine for COVID-19: why might they be hazardous?
por: Funck-Brentano, Christian, et al.
Publicado: (2020)

“Off-label” use of hydroxychloroquine, azithromycin, lopinavir-ritonavir and chloroquine in COVID-19: A survey of cardiac adverse drug reactions by the French Network of Pharmacovigilance Centers
por: Gérard, Alexandre, et al.
Publicado: (2020)

Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study
por: Johnson, Douglas B., et al.
Publicado: (2019)

Azithromycin/hydroxychloroquine/methylprednisolone: Various toxicities: case report
Publicado: (2021)

Azithromycin/hydroxychloroquine: Various toxicities: 4 case reports
Publicado: (2021)

Azithromycin/hydroxychloroquine/methylprednisolone: Various toxicities: case report
Publicado: (2021)

Immune Checkpoint Inhibitor Myocarditis Treatment Strategies and Future Directions
por: Moslehi, Javid, et al.
Publicado: (2022)

Anticancer drugs and COVID-19 antiviral treatments in patients with cancer: What can we safely use?
por: Gougis, Paul, et al.
Publicado: (2020)

Azithromycin/favipiravir/hydroxychloroquine: Various toxicities: 7 case reports
Publicado: (2022)

French Pharmacovigilance Public System and COVID-19 Pandemic
por: Grandvuillemin, Aurélie, et al.
Publicado: (2020)

Pharmacovigilance follow-up of patients in the context of the COVID-19 pandemic
por: Grandvuillemin, Aurélie, et al.
Publicado: (2023)

Drug-associated hyperammonaemia: a Bayesian analysis of the WHO Pharmacovigilance Database
por: Balcerac, Alexander, et al.
Publicado: (2022)

Pharmacokinetics and pharmacodynamics of hydroxychloroquine in hospitalized patients with COVID-19
por: Zahr, Noël, et al.
Publicado: (2021)

Comparaison des caractéristiques et des pronostics des patients avec et sans cancer actif hospitalisés pour une infection à SARS-CoV-2
por: Fenioux, Charlotte, et al.
Publicado: (2021)

Ascorbic-acid, azithromycin and hydroxychloroquine: Various toxicities: 3 case reports
Publicado: (2021)

QT interval monitoring for inpatient treated with hydroxychloroquine/azithromycin association in the context of SARS-CoV-2 pandemic
por: Bun, S., et al.
Publicado: (2021)

Calcitonin gene-related peptide-targeting drugs and Raynaud’s phenomenon: a real-world potential safety signal from the WHO pharmacovigilance database
por: Gérard, Alexandre O., et al.
Publicado: (2022)

Effects of cardiac toxicity of combination therapy with hydroxychloroquine and azithromycin in COVID-19 patients
por: Yendrapalli, Usha, et al.
Publicado: (2021)

Hydroxychloroquine- and azithromycin-related heart disorders
Publicado: (2020)

Hydroxychloroquine + azithromycin treatment in elderly patients
por: Gautret, Philippe, et al.
Publicado: (2021)

Hydroxychloroquine or chloroquine +/- azithromycin: heart disorders
Publicado: (2022)

Pharmacovigilance des médicaments et des vaccins contre la COVID-19 durant la pandémie : comment le Réseau français des centres régionaux de pharmacovigilance a relevé le défi ?
por: Jonville-Bera, Annie Pierre, et al.
Publicado: (2023)

QT interval prolongation with hydroxychloroquine plus azithromycin
Publicado: (2020)

Excessive lysosomal ion-trapping of hydroxychloroquine and azithromycin
por: Derendorf, Hartmut
Publicado: (2020)

Hydroxychloroquine-azithromycin for COVID-19 – Warranted or dangerous?
por: Popescu, Corneliu P., et al.
Publicado: (2020)

Hydroxychloroquine and azithromycin as a treatment of COVID-19
por: Fanin, Alice, et al.
Publicado: (2020)

Insights on the Evidence of Cardiotoxicity of Hydroxychloroquine Prior and During COVID‐19 Epidemic
por: Romani, Serena, et al.
Publicado: (2020)

Infections associated with clozapine: a pharmacovigilance study using VigiBase(®)
por: Chrétien, Basile, et al.
Publicado: (2023)

Impact of Azithromycin and/or Hydroxychloroquine on Hospital Mortality in COVID-19
por: Albani, Filippo, et al.
Publicado: (2020)

Azithromycin/hydroxychloroquine: QTc interval prolongation: case report
Publicado: (2020)

Anticoagulants/azithromycin/hydroxychloroquine: Spontaneous haematoma: case report
Publicado: (2020)

Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19
por: Cavalcanti, Alexandre B., et al.
Publicado: (2020)

Azithromycin/hydroxychloroquine: Prolongation of the QT interval: case report
Publicado: (2020)

Azithromycin/ceftriaxone/hydroxychloroquine: Acute urticaria: case report
Publicado: (2020)

Azithromycin/hydroxychloroquine: SDRIFE-like rash: case report
Publicado: (2021)

Azithromycin/hydroxychloroquine: QTc interval prolongation: case report
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_7qfqaf5d8a7jcn0k75gks434g2